| Constance Phylea Barnes-woods, MD | |
|
2100 Highway 61 N, Vicksburg, MS 39183-8211 | |
| (601) 883-3391 | |
| (601) 883-3318 |
| Full Name | Constance Phylea Barnes-woods |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 2100 Highway 61 N, Vicksburg, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538521901 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 26688 (Mississippi) | Primary |
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge.
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.
The response to infection is highly variable from one individual to another. The Milieu Intérieur consortium, coordinated by Prof. Matthew Albert (Immunobiology of dendritic cells Unit, Institut Pasteur / Inserm) and Dr Lluis Quintana-Murci (Human Evolutionary Genetics Unit, Institut Pasteur / CNRS) seek to establish the parameters that characterize the immune system of healthy individuals and its natural variability.
Major life events such as marriage, death of a loved one or bankruptcy all affect our wellbeing. Now, for the first time, researchers have compared the differing impact of these events on the happiness and life satisfaction and how long that impact lasts.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
› Verified 6 days ago
| Entity Name | Beanstalk Pediatrics, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740967520 PECOS PAC ID: 3274993522 Enrollment ID: O20230718001836 |
News Archive
Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge.
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.
The response to infection is highly variable from one individual to another. The Milieu Intérieur consortium, coordinated by Prof. Matthew Albert (Immunobiology of dendritic cells Unit, Institut Pasteur / Inserm) and Dr Lluis Quintana-Murci (Human Evolutionary Genetics Unit, Institut Pasteur / CNRS) seek to establish the parameters that characterize the immune system of healthy individuals and its natural variability.
Major life events such as marriage, death of a loved one or bankruptcy all affect our wellbeing. Now, for the first time, researchers have compared the differing impact of these events on the happiness and life satisfaction and how long that impact lasts.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Constance Phylea Barnes-woods, MD 2100 Highway 61 N, Vicksburg, MS 39183-8211 Ph: (601) 883-5000 | Constance Phylea Barnes-woods, MD 2100 Highway 61 N, Vicksburg, MS 39183-8211 Ph: (601) 883-3391 |
News Archive
Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge.
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.
The response to infection is highly variable from one individual to another. The Milieu Intérieur consortium, coordinated by Prof. Matthew Albert (Immunobiology of dendritic cells Unit, Institut Pasteur / Inserm) and Dr Lluis Quintana-Murci (Human Evolutionary Genetics Unit, Institut Pasteur / CNRS) seek to establish the parameters that characterize the immune system of healthy individuals and its natural variability.
Major life events such as marriage, death of a loved one or bankruptcy all affect our wellbeing. Now, for the first time, researchers have compared the differing impact of these events on the happiness and life satisfaction and how long that impact lasts.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
› Verified 6 days ago
Lisa D Fairchild, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Thomas C Moore, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1115 N Frontage Rd, Vicksburg, MS 39180 Phone: 601-634-8790 | |
Dr. Izzeddin Kamelmaz, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-6001 | |
Elizabeth N Roy, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Lauren Dean Mckinney, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Geri L Weiland, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 |